80 related articles for article (PubMed ID: 34265433)
21. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
[TBL] [Abstract][Full Text] [Related]
22. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J
BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.
Krawczyk P; Grenda A; Terlecka P; Błach J; Wojas-Krawczyk K; Kucharczyk T; Chmielewska I; Kieszko R; Jarosz B; Gil M; Reszka K; Milanowski J
Sci Rep; 2021 Oct; 11(1):20939. PubMed ID: 34686712
[TBL] [Abstract][Full Text] [Related]
24. Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Clarke JM; Patel JD; Robert F; Kio EA; Thara E; Ross Camidge D; Dunbar M; Nuthalapati S; Dinh MH; Bach BA
Lung Cancer; 2021 Nov; 161():180-188. PubMed ID: 34607210
[TBL] [Abstract][Full Text] [Related]
25. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Peters S; Danson S; Ejedepang D; Dafni U; Hasan B; Radcliffe HS; Bustin F; Crequit J; Coate L; Guillot M; Surmont V; Rauch D; Rudzki J; O'Mahony D; Barneto Aranda I; Scherz A; Tsourti Z; Roschitzki-Voser H; Pochesci A; Demonty G; Stahel RA; O'Brien M
Lung Cancer; 2021 Nov; 161():76-85. PubMed ID: 34543941
[TBL] [Abstract][Full Text] [Related]
26. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
27. Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers-Reply.
Wang J; Leaw SJ; Lu S
JAMA Oncol; 2021 Oct; 7(10):1580-1581. PubMed ID: 34410312
[No Abstract] [Full Text] [Related]
28. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
Tsakiridis T; Pond GR; Wright J; Ellis PM; Ahmed N; Abdulkarim B; Roa W; Robinson A; Swaminath A; Okawara G; Wierzbicki M; Valdes M; Levine M
JAMA Oncol; 2021 Sep; 7(9):1333-1341. PubMed ID: 34323924
[TBL] [Abstract][Full Text] [Related]
29. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
Skinner H; Hu C; Tsakiridis T; Santana-Davila R; Lu B; Erasmus JJ; Doemer AJ; Videtic GMM; Coster J; Yang AX; Lee RY; Werner-Wasik M; Schaner PE; McCormack SE; Esparaz BT; McGarry RC; Bazan J; Struve T; Paulus R; Bradley JD
JAMA Oncol; 2021 Sep; 7(9):1324-1332. PubMed ID: 34323922
[TBL] [Abstract][Full Text] [Related]
30. Targeting
Meador CB; Sequist LV; Piotrowska Z
Cancer Discov; 2021 Sep; 11(9):2145-2157. PubMed ID: 34301786
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.
Lu S; Pan H; Wu L; Yao Y; He J; Wang Y; Wang X; Fang Y; Zhou Z; Wang X; Cai X; Yu Y; Ma Z; Min X; Yang Z; Cao L; Yang H; Shu Y; Zhuang W; Cang S; Fang J; Li K; Yu Z; Cui J; Zhang Y; Li M; Wen X; Zhang J; Li W; Shi J; Xu X; Zhong D; Wang T; Zhu J
Signal Transduct Target Ther; 2023 Jun; 8(1):249. PubMed ID: 37385995
[TBL] [Abstract][Full Text] [Related]
32. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
Shi Y; Fang J; Hao X; Zhang S; Liu Y; Wang L; Chen J; Hu Y; Hang X; Li J; Liu C; Zhang Y; Wang Z; Hu Y; Gu K; Huang J; Zhang L; Shan J; Ouyang W; Zhao Y; Zhuang W; Yu Y; Zhao J; Zhang H; Lu P; Li W; Si M; Ge M; Geng H
Signal Transduct Target Ther; 2022 Jan; 7(1):25. PubMed ID: 35087031
[TBL] [Abstract][Full Text] [Related]
33. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
34. Advances in systemic therapy for non-small cell lung cancer.
Miller M; Hanna N
BMJ; 2021 Nov; 375():n2363. PubMed ID: 34753715
[TBL] [Abstract][Full Text] [Related]
35. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Liu SY; Bao H; Wang Q; Mao WM; Chen Y; Tong X; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Dong S; Zhang XC; Su J; Yang JJ; Yang XN; Zhou Q; Wu X; Shao Y; Zhong WZ; Wu YL
Nat Commun; 2021 Nov; 12(1):6450. PubMed ID: 34750392
[TBL] [Abstract][Full Text] [Related]
36. Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy.
Wu J; Hu Y; Abdihamid O; Huang G; Xiao S; Li B
Front Oncol; 2021; 11():684865. PubMed ID: 34722239
[TBL] [Abstract][Full Text] [Related]
37. Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.
Wang P; Li Y; Lv D; Yang L; Ding L; Zhou J; Hong W; Chen Y; Zhang D; He S; Zhou J; Wang K
Signal Transduct Target Ther; 2021 Nov; 6(1):374. PubMed ID: 34719670
[TBL] [Abstract][Full Text] [Related]
38. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L; Hatipoglu E; Robert de Massy M; Litchfield K; Beattie G; Rowan A; Schnidrig D; Thompson R; Byrne F; Horswell S; Fotiadis N; Hazell S; Nicol D; Shepherd STC; Fendler A; Mason R; Del Rosario L; Edmonds K; Lingard K; Sarker S; Mangwende M; Carlyle E; Attig J; Joshi K; Uddin I; Becker PD; Sunderland MW; Akarca A; Puccio I; Yang WW; Lund T; Dhillon K; Vasquez MD; Ghorani E; Xu H; Spencer C; López JI; Green A; Mahadeva U; Borg E; Mitchison M; Moore DA; Proctor I; Falzon M; Pickering L; Furness AJS; Reading JL; Salgado R; Marafioti T; Jamal-Hanjani M; ; Kassiotis G; Chain B; Larkin J; Swanton C; Quezada SA; Turajlic S;
Cancer Cell; 2021 Nov; 39(11):1497-1518.e11. PubMed ID: 34715028
[TBL] [Abstract][Full Text] [Related]
39. New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.
Villa M; Sharma GG; Manfroni C; Cortinovis D; Mologni L
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680298
[TBL] [Abstract][Full Text] [Related]
40. [Recommendations from Experts in the Management of Adverse Reactions
to ALK Inhibitors (2021 Version)].
Wang K; Li J; Sun J; Li L; Zhang X; Zhang J; Yu M; Ye X; Zhang M; Zhang Y; Yao W; Huang M
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):815-828. PubMed ID: 34670356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
